1. PMDA. Guidelines for Non-Clinical Pharmacokinetic Studies. No 469. 1998.
2. Model-Informed Drug Development Pilot Program. https://www.fda.gov/drugs/development-resources/model-informed-drug-development-paired-meeting-program. Accessed 8 May 2023.
3. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Physiologically Based Pharmacokinetic Analyses—Format and Content Guidance for Industry. 2019.
4. EMA. Reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. European Medicines Agency. 2018. https://www.ema.europa.eu/en/reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation-scientific-guideline. Accessed 10 Apr 2023.
5. Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, et al. Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther. 2018;104(1):88–110.